Cibus to Report Fourth Quarter 2025 Financial Results on March 17, 2026 After the Market Close and Host Conference Call
Cibus (Nasdaq: CBUS) will report fourth quarter 2025 financial results on Tuesday, March 17, 2026 after the market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cibus (Nasdaq: CBUS) will report fourth quarter 2025 financial results on Tuesday, March 17, 2026 after the market close. Management will host a conference call and audio webcast at 4:30 p.m. ET to discuss results and company updates.
Dial-in numbers, conference ID, replay details, and a live webcast with slides will be available on the company's Investor Events page; an archived webcast will remain available for 90 days.
Details
News Market Reaction – CBUS
On Mar 4, the first trading day after this news, CBUS closed 5.67% below the previous close.
Data tracked by StockTitan Argus for the Mar 4 session.
Key Figures
- Earnings date
- March 17, 2026
- Fourth quarter 2025 financial results release
- Conference call time
- 4:30 p.m. ET
- Start time for Q4 2025 results call
- US participant number
- +1-800-343-5172
- Domestic dial-in for results conference call
- International number
- +1-203-518-9856
- International dial-in for results conference call
- Conference ID
- CIBUS / 24287
- ID required to access the conference call
- Replay end date
- March 31, 2026
- Last day replay of call is available by phone
- Replay passcode
- 11160915
- Passcode for dial-in replay access
- Webcast archive period
- 90 days
- Duration archived webcast remains on company website
Historical Context
-
Joined UK-funded precision breeding project targeting Light Leaf Spot resistance.
-
Priced $20M underwritten stock offering at $1.50 per share.
-
Announced proposed underwritten stock offering under effective Form S-3.
-
Non-binding LOI with Interoc to commercialize HT rice traits in Latin America.
-
Welcomed positive EU NGT legislation outcome supporting gene-edited plants.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies, today announced that the company will report fourth quarter 2025 financial results on Tuesday, March 17, 2026. Cibus’ management team will host a conference call and audio webcast at 4:30 p.m. ET on that day to discuss the financial results and other company updates.
Title: Cibus, Inc. Fourth Quarter 2025 Results Conference Call
Event Date: Tuesday, March 17, 2026
Time: 4:30 p.m. ET
Participant Numbers: +1-800-343-5172 (U.S.), +1-203-518-9856 (International)
The conference ID “CIBUS” or 24287 will be required for entry
Event Link: https://investor.cibus.com/events
For interested individuals unable to join the conference call, a dial-in replay of the call will be available through Tuesday, March 31, 2026, and can be accessed by dialing +1-844-512-2921 (U.S.), +1-412-317-6671 (International) and entering replay passcode: 11160915.
A live audio webcast of the call, along with accompanying slides, will be available under "News & Events” in the Investor section of the Company's website, investor.cibus.com. An archived webcast will be available on the Company's website for 90 days after the event.
About Cibus
Cibus is a leader in developing traits (characteristics) that address critical productivity, yield and sustainability challenges. Cibus’ proprietary high-throughput gene-editing technologies drive its long-term focus on productivity traits for farmers for the major global row crops. Cibus is not a seed company. It is a technology company that uses its gene editing technologies to develop plant traits at a fraction of the time and cost of conventional breeding and to license them to customers in exchange for royalties, leveraging its strong partnerships across the seed industry as a whole.
Cibus Contacts:
Investor Relations
Jeff Sonnek – ICR
jeff.sonnek@icrinc.com
Media Relations
Colin Sanford
colin@bioscribe.com
203-918-4347
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.